Nu mangler kun en endelig vedtagelse i EU-Parlamentet, før lovforslag om at udskyde deadlines for nye krav til medicinsk udstyr. er en realitet. | Photo: Thomas Borberg/Ritzau Scanpix

Another hurdle overcome in delaying MDR deadline

EU member countries have voted unanimously to adopt an EU Commission proposal to stagger the implementation of the new Medical Device Regulation. Now, only the EU Parliament’s vote remains.

For subscribers

Pharma & biotech

Novo Nordisk hopes to retain employees with share gift

All Novo Nordisk employees have been offered 37 restricted stock units, which can be turned into real B shares in Aug. 2026.

For subscribers

Other

Top news from MedWatch this week

Miss anything?

Luja can potentially solve a long-lived UTI problem for people who need help with bladder control issues by using new micro-hole technology

Medtech

Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps

A male catheter is the Danish medtech company’s biggest launch in half a decade – and CFO Anders Lonning-Skovgaard expects the 12-month rollout to be nothing but smooth sailing.

For subscribers

Did you read?

Novo Nordisk CEO rakes in cash in record year

Being at the top of Denmark’s most valuable company is lucrative, Novo Nordisk reveals in its annual report – and Chief Executive Lars Fruergaard Jørgensen is making a killing there.

For subscribers

Medtech

Coloplast launches male catheter featuring new technology

The Danish medtech company hopes to win market shares with a new product, Luja, heralding it a ”growth driver within continence care.”

For subscribers

Medtech

Coloplast's bottom line disappoints in otherwise strong report

Despite increasing revenues, Coloplast has still managed to take a step back on its profit in Q1’22/23.

For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Jobs

See all jobs

Pharma & biotech

ALK forecasts lower growth in 2023 than strong 2022 result

The allergy firm thinks 7–11% growth in 2023 is likely after a strong 2022 performance meets an upgraded guidance from the summer.

For subscribers

Did you read?

Novo Nordisk hopes to retain employees with share gift

All Novo Nordisk employees have been offered 37 restricted stock units, which can be turned into real B shares in Aug. 2026.

For subscribers

Pharma & biotech

China accepts regulatory filing for ALK allergy tablet

ALK says 100 million people suffer house dust mite allergies in China but only 500,000 patients receive allergy immunotherapy.

For subscribers

Pharma & biotech

Dupixent becomes ninefold blockbuster

Sales of Sanofi’s multi-incidation drug, Dupixent, are growing and on track to pass a huge milestone in 2023.

For subscribers

Medtech

Unilabs and Siemens Healthineers enter million-euro strategic partnership

The diagnostic services provider is buying Siemens Healthineers-developed equipment valued at EUR 200m.

For subscribers

Photo: Mike Blake/Reuters/Ritzau Scanpix

Pharma & biotech

Eli Lilly raises 2023 expectations

A new forecasted tax rate for the fiscal year to come means Lilly can upgrade some expectations, reveals the company’s fourth-quarter report.

For subscribers

Did you read?

Novo Nordisk declared world's best place to work in 2022

The Best Places to Work organization has released its 2022 list of the best workplaces across the world, and Danish Novo Nordisk shines at the top.

For subscribers

Latest news

See all

Jobs

Article series: Hearing health

Is William Demant Invest seeking hostile takeover of GN? Three scenarios in play

For subscribers

Read the article here

Pharma & biotech

Europe pharma sector risks lagging the world, say drug chiefs

Chief executives of Novartis, GSK, and Novo Nordisk say healthcare must become an urgent priority in Europe, else the region risks falling behind the rest of the world.

For subscribers

Photo: Fabian Bimmer/Reuters/Ritzau Scanpix

Pharma & biotech

Supply issues to continue in 2023, reports Novo Nordisk

Investing massively into increasing production capacity, Novo Nordisk hopes to increase its drug supply, though 2023 will still see ”periodic supply constraints,” informs Novo CFO Karsten Munk Knudsen.

For subscribers

Lars Fruergaard Jørgensen, CEO of Novo Nordisk | Photo: Stine Bidstrup

Pharma & biotech

Novo Nordisk CEO says obesity is "obviously a big market"

Analysts value the future obesity market in the billions of dollars – and though coy about his own expectations, CEO Lars Fruergaard Jørgensen says Novo Nordisk has ”a very, very significant opportunity.”

For subscribers

Novo Nordisk CEO rakes in cash in record year

Being at the top of Denmark’s most valuable company is lucrative, Novo Nordisk reveals in its annual report – and Chief Executive Lars Fruergaard Jørgensen is making a killing there.

For subscribers

Medtech

Analyst: China headwinds will dampen Coloplast's first quarter

Covid-19 shutdowns in China have restricted patients’ hospital access, which Danish bank Sydbank says will hurt revenue inflows for the Danish medtech company.

For subscribers

Photo: Andrew Kelly/Reuters/Ritzau Scanpix

Hearing health

Bank lowers Demant share target week before annual report

Jyske Bank says investors will want to pay attention next week to Demant’s 2023 outlook which is likely to contain cautious expectations for the year ahead.

For subscribers

Photo: Marcio Jose Sanchez/AP/Ritzau Scanpix

Medtech

Boston Scientific's endoscope sales beat predictions

The US-based medtech firm’s outlook for 2023 is a tad less optimistic than what analysts had hoped for.

For subscribers

Hearing health

Nordea spots increased chance of GN being acquired

Considering recent events and the current climate, Nordea estimates that the chance of someone buying GN Group ”within a foreseeable future is very high.”

For subscribers

Viatris's headquaters in Pittsburgh, Pennsylvania, US | Photo: Viatris/PR.

Pharma & biotech

Novo Nordisk sues Viatris over copycat Wegovy

A market authorization application from US-based generics maker Viatris for a copy version of obesity treatment Wegovy breaches five of Novo Nordisk’s patents, claims the company in a lawsuit.

For subscribers

Hearing health

GN, Sivantos, Sonova lose Veterans Affairs market shares in December

At the very end of 2022, the three hearing aid manufacturers lost terrain at the US public hearing aid sales channel – while Demant and Starkey gained ground.

For subscribers

Pharma & biotech

Novo Nordisk meets upgraded guidance, sets new revenue record

The Danish drugmaker’s top and bottom lines have increased considerably.

For subscribers

Lars Fruergaard Jørgensen, CEO at Novo Nordisk | Photo: Stine Bidstrup

Pharma & biotech

Potential blockbuster submitted by Novo Nordisk for European approval

The EMA can begin reviewing hemophilia treatment concizumab, which used to carry the orphan drug badge until recently, when the company decided not to take advantage of the status.

For subscribers

Pharma & biotech

Novo Nordisk doubles obesity sales in 2022

Wegovy and Saxenda set new records in fiscal 2022, during which particularly the former gave a strong performance near the end, exceeding analysts Q4 expectations by millions of dollars.

For subscribers

Pharma & biotech

Novo Nordisk predicts wide range for 2023 sales growth

The Danish drugmaker has released its 2023 guidance with a sales growth expectation of 13–19%. (Updated)

For subscribers

Photo: Arnd Wiegmann/Reuters/Ritzau Scanpix

Pharma & biotech

Novartis beats Kesimpta sales expectations in Q4

Multiple sclerosis treatment Kesimpta, based on Genmab-developed ofatumumab, has generated more than analysts predicted in Q4’22.

For subscribers

Jobs

See all jobs

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Another hurdle overcome in delaying MDR deadline

Novo Nordisk hopes to retain employees with share gift

Top news from MedWatch this week

Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps

Did you read?

Novo Nordisk CEO rakes in cash in record year

Coloplast launches male catheter featuring new technology

Coloplast's bottom line disappoints in otherwise strong report

Sign up for our newsletter

Jobs

ALK forecasts lower growth in 2023 than strong 2022 result

Did you read?

Novo Nordisk hopes to retain employees with share gift

China accepts regulatory filing for ALK allergy tablet

Dupixent becomes ninefold blockbuster

Unilabs and Siemens Healthineers enter million-euro strategic partnership

Eli Lilly raises 2023 expectations

Did you read?

Novo Nordisk declared world's best place to work in 2022

Latest news

Jobs

Article series: Hearing health

Is William Demant Invest seeking hostile takeover of GN? Three scenarios in play

Europe pharma sector risks lagging the world, say drug chiefs

Supply issues to continue in 2023, reports Novo Nordisk

Novo Nordisk CEO says obesity is "obviously a big market"

Most read

Novo Nordisk CEO rakes in cash in record year

Analyst: China headwinds will dampen Coloplast's first quarter

Bank lowers Demant share target week before annual report

Boston Scientific's endoscope sales beat predictions

Nordea spots increased chance of GN being acquired

Novo Nordisk sues Viatris over copycat Wegovy

GN, Sivantos, Sonova lose Veterans Affairs market shares in December

Novo Nordisk meets upgraded guidance, sets new revenue record

Potential blockbuster submitted by Novo Nordisk for European approval

Novo Nordisk doubles obesity sales in 2022

Novo Nordisk predicts wide range for 2023 sales growth

Novartis beats Kesimpta sales expectations in Q4

Jobs